Paul J Kennedy

US Patent:

7151087, Dec 19, 2006

Filed:

Oct 31, 2003

Appl. No.:

10/700313

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward A. Berger - Rockville MD, US
Philip M. Murphy - Rockville MD, US
Christopher C. Broder - Rockville MD, US
Paul E. Kennedy - Silver Spring MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Resources - Washington DC

International Classification:

A61K 38/00

US Classification:

514 13, 514 14

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

20070087990, Apr 19, 2007

Filed:

Nov 7, 2006

Appl. No.:

11/594375

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward Berger - Rockville MD, US
Philip Murphy - Rockville MD, US
Christopher Broder - Rockville MD, US
Paul Kennedy - Silver Spring MD, US

International Classification:

A61K 31/70
C12P 21/06
A01N 43/04

US Classification:

514044000, 435069100

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

20080241167, Oct 2, 2008

Filed:

Mar 7, 2008

Appl. No.:

12/044845

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward A. Berger - Rockville MD, US
Philip M. Murphy - Rockville MD, US
Christopher C. Broder - Rockville MD, US
Paul E. Kennedy - Silver Spring MD, US

International Classification:

A61K 39/395
C12N 5/06
G01N 33/566
G01N 33/53
C12Q 1/70
C12Q 1/02
A61K 31/7052
C12N 15/87
A61P 31/18

US Classification:

4241721, 435375, 436501, 435 72, 435 5, 435 29, 514 44, 435440

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.